Results 71 to 80 of about 21,799 (237)
THE NOVEL BIOSIMILAR OF FOLLITROPIN ALPHA TO BE MANUFACTURED IN RUSSIA STARTING FROM 2017
Акушерство, гинекология и репродукция, 2017 Within the framework of the 27th international conference «Reproductive technologies today and tomorrow», the first Russia-made follitropin alfa biosimilar for controlled ovarian stimulation in assisted reproductive technologies (ART) was presented.
I. I. Vorobiev +2 more
doaj +1 more source
PMS62 A Multi-Country Physician Survey On Patient Eligibility And Use Of Biologics In Rheumatoid Arthritis (Ra), Ankylosing Spondylitis (As) And Psoriatic Arthritis (Psa) In European Union (Eu) [PDF]
, 2013 Item does not contain ...
Narayanan, S. +3 more
core +1 more source
Drug Testing and Analysis, EarlyView.A basic EPO IEF profile was identified in patients with familial erythropoiesis linked to mutations in noncoding parts of EPO gene. Comparison of blood and urine EPO profiles from these patients differed from adult wild‐type EPO (WT) and from Eprex‐administered patients. Patients' EPO do not differ from WT EPO after analysis using SDS‐PAGE/SAR‐PAGE. It
Laurent Martin +9 more
wiley +1 more source
Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays [PDF]
, 2017 Background: The commercialization of CT-P13, an infliximab (IFX) biosimilar, has the potential to decrease health-related costs and enhance access to biological therapies.
Cláudia Camila Dias +6 more
core +1 more source
European Policy Analysis, EarlyView.ABSTRACT Policy process research has excelled in explaining structural policy change within national settings, but extensions and applications to the EU level have long proven challenging for scholars. Given that the EU is currently experiencing its longest period of Treaty stability since the 1980s—having evolved into a sui generis political system ...
Vassilis Karokis‐Mavrikos
wiley +1 more source
Biases affecting injected doses of an experimental drug during clinical trials. [PDF]
, 2016 During clinical trials, researchers rarely question nominal doses specified on labels of investigational products, overlooking the potential for inaccuracies that may result when calculating pharmacokinetic and pharmacodynamic parameters.
Biollaz, J. +6 more
core +2 more sources
Head &Neck, EarlyView.ABSTRACT Background The expanding use of systemic therapies for recurrent and metastatic head and neck cancer has raised major concerns regarding affordability and equitable access, particularly across countries with differing income levels and health financing structures.
Arjun Gurmeet Singh +9 more
wiley +1 more source
Ten years of biosimilar recombinant human growth hormone in Europe
Drug Design, Development and Therapy, 2017 Paul Saenger Division of Pediatric Endocrinology, Department of Pediatrics, Winthrop University Hospital, Mineola, NY, USA Abstract: Recombinant human growth hormone (rhGH) has been in clinical use for more than 30 years.
Saenger P
doaj
Neurology and Therapy, 2019 The use of biosimilar drugs for multiple sclerosis (MS) has become widespread in Latin America, with the goal of reducing costs of treatments, promoting the sustainability of healthcare systems, and improving patient access to these therapies.
Judith Steinberg +14 more
doaj +1 more source
Predictive glycoengineering of biosimilars using a Markov chain glycosylation model [PDF]
, 2016 Biosimilar drugs must closely resemble the pharmacological attributes of innovator products to ensure safety and efficacy to obtain regulatory approval. Glycosylation is one critical quality attribute that must be matched, but it is inherently difficult ...
Hansen, Anders Holmgaard +4 more
core +1 more source